Showing results (201-210 of 224) with videos related to

Sort By:
Pageof 23
Blood|September 23, 2011
PIM2 inhibition as a rational therapeutic approach in B-cell lymphomaCristina Gómez-Abad, Helena Pisonero, Carmen Blanco-Aparicio, et al.
Molecular Cell|July 2, 2019
lncRNA-Induced Spread of Polycomb Controlled by Genome Architecture, RNA Abundance, and CpG Island DNAMegan D Schertzer, Keean C A Braceros, Joshua Starmer, et al.
Cell Metabolism|March 13, 2012
Pten positively regulates brown adipose function, energy expenditure, and longevityAna Ortega-Molina, Alejo Efeyan, Elena Lopez-Guadamillas, et al.
Haematologica|February 6, 2010
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphomaMagdalena B Wozniak, Raquel Villuendas, James R Bischoff, et al.
Molecular Cell|March 21, 2025
Isogenic comparison of Airn and Xist reveals core principles of Polycomb recruitment by lncRNAsJackson B Trotman, Elizabeth W Abrash, McKenzie M Murvin, et al.
Journal of Medicinal Chemistry|January 20, 2021
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)Zhuming Zhang, Peter J Connolly, Heng Keang Lim, et al.
Bioorganic & Medicinal Chemistry Letters|February 14, 2012
Imidazo[1,2-a]pyrazines as novel PI3K inhibitorsSonia Martínez González, Ana Isabel Hernández, Carmen Varela, et al.
Molecular Cancer Therapeutics|March 2, 2021
Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate CancerJonathan R Branch, Tammy L Bush, Vineet Pande, et al.
European Urology|August 2, 2005
Innovations in serum and urine markers in prostate cancer current European research in the P-Mark projectM P M Q van Gils, U H Stenman, J A Schalken, et al.
Investigational New Drugs|May 25, 2012
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinasesTeresa G Granda, David Cebrián, Sonia Martínez, et al.
Pageof 23